Back to results

TerminatedPhase 1Phase 2

A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease

NCT06822517

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Investigative Site

Fountain Valley, California, United States

+22 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2025-03-05
Enrollment: 29 participants
Sponsor: Ventus Therapeutics U.S., Inc.
Purpose: treatment

Locations (23)

Investigative SiteFountain Valley, California, United States
Investigative SiteSan Jose, California, United States
Investigative SiteWest Hills, California, United States
Investigative SiteEnglewood, Colorado, United States
Investigative SiteAventura, Florida, United States
Investigative SiteBoca Raton, Florida, United States
Investigative SiteCoral Gables, Florida, United States
Investigative SiteCoral Springs, Florida, United States
Investigative SiteCutler Bay, Florida, United States
Investigative SiteDaytona Beach, Florida, United States
Investigative SiteDoral, Florida, United States
Investigative SiteJacksonville, Florida, United States
Investigative SiteMaitland, Florida, United States
Investigative SiteMiami, Florida, United States
Investigative SiteMiami, Florida, United States
Investigative SiteWinter Park, Florida, United States
Investigative SiteScarborough, Maine, United States
Investigative SiteFarmington Hills, Michigan, United States
Investigative SiteAbington, Pennsylvania, United States
Investigative SiteMemphis, Tennessee, United States
Investigative SiteCypress, Texas, United States
Investigative SiteRound Rock, Texas, United States
Investigative SiteSpokane, Washington, United States

A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease — TrialFind